Shasun Pharma to begin clinical trial for cancer cure

Ltd is developing injectable radioactive nanoparticles to treat solid cancer to mark its entry into nanotechnology. The company, one of the largest producers of with more than 50 per cent of the global market share, is expected to commence clinical trials on the drug candidate within a year.

It has entered into a joint venture with the Nanoparticle Biochem, Inc (NBI), partly owned by the University of Missouri, Colombia, in August last year to develop the latter's lead molecule NBI-29 to treat prostate cancer. The nanotech product would be developed under the 50:50 JV company Shasun NBI LLC.

“The multi-centric, multi-national clinical trial for the injectible treatment of solid cancer would be conducted by Shasun starting from India within a year,” said S Abhayakumar, director (Operations, Strategy,Technical,Operations,HR, and Marketing (STOHRM)), Shasun Pharmaceuticals.

Shasun will have the complete rights on patent, marketing and manufacturing of the product. The drug candidate is undergoing animal studies, at present.

“We are discussing with our partner to set up a manufacturing plant in Chennai for the product, once the studies complete successfully,” he added. However, he refused to reveal the investment involved.

The gold particles would be dipped into a nuclear reactor and coat it with a drug to prepare the injectable form, which could be directly inducted to the solid tumour. It would help in treating the cancer right at the place where it exists, he said.

Shasun is currently into manufacturing of Ibuprofen and its derivatives, ranitidine and nizatidine catering to the global market.

image
Business Standard
177 22
Business Standard

Shasun Pharma to begin clinical trial for cancer cure

Gireesh Babu  |  Chennai 



Ltd is developing injectable radioactive nanoparticles to treat solid cancer to mark its entry into nanotechnology. The company, one of the largest producers of with more than 50 per cent of the global market share, is expected to commence clinical trials on the drug candidate within a year.

It has entered into a joint venture with the Nanoparticle Biochem, Inc (NBI), partly owned by the University of Missouri, Colombia, in August last year to develop the latter's lead molecule NBI-29 to treat prostate cancer. The nanotech product would be developed under the 50:50 JV company Shasun NBI LLC.

“The multi-centric, multi-national clinical trial for the injectible treatment of solid cancer would be conducted by Shasun starting from India within a year,” said S Abhayakumar, director (Operations, Strategy,Technical,Operations,HR, and Marketing (STOHRM)), Shasun Pharmaceuticals.

Shasun will have the complete rights on patent, marketing and manufacturing of the product. The drug candidate is undergoing animal studies, at present.

“We are discussing with our partner to set up a manufacturing plant in Chennai for the product, once the studies complete successfully,” he added. However, he refused to reveal the investment involved.

The gold particles would be dipped into a nuclear reactor and coat it with a drug to prepare the injectable form, which could be directly inducted to the solid tumour. It would help in treating the cancer right at the place where it exists, he said.

Shasun is currently into manufacturing of Ibuprofen and its derivatives, ranitidine and nizatidine catering to the global market.

RECOMMENDED FOR YOU

Shasun Pharma to begin clinical trial for cancer cure

Shasun Pharmaceuticals Ltd is developing injectable radioactive nanoparticles to treat solid cancer to mark its entry into nanotechnology. The company, one of the largest producers of pain-killer drug Ibuprofen with more than 50 per cent of the global market share, is expected to commence clinical trials on the drug candidate within a year.

Ltd is developing injectable radioactive nanoparticles to treat solid cancer to mark its entry into nanotechnology. The company, one of the largest producers of with more than 50 per cent of the global market share, is expected to commence clinical trials on the drug candidate within a year.

It has entered into a joint venture with the Nanoparticle Biochem, Inc (NBI), partly owned by the University of Missouri, Colombia, in August last year to develop the latter's lead molecule NBI-29 to treat prostate cancer. The nanotech product would be developed under the 50:50 JV company Shasun NBI LLC.

“The multi-centric, multi-national clinical trial for the injectible treatment of solid cancer would be conducted by Shasun starting from India within a year,” said S Abhayakumar, director (Operations, Strategy,Technical,Operations,HR, and Marketing (STOHRM)), Shasun Pharmaceuticals.

Shasun will have the complete rights on patent, marketing and manufacturing of the product. The drug candidate is undergoing animal studies, at present.

“We are discussing with our partner to set up a manufacturing plant in Chennai for the product, once the studies complete successfully,” he added. However, he refused to reveal the investment involved.

The gold particles would be dipped into a nuclear reactor and coat it with a drug to prepare the injectable form, which could be directly inducted to the solid tumour. It would help in treating the cancer right at the place where it exists, he said.

Shasun is currently into manufacturing of Ibuprofen and its derivatives, ranitidine and nizatidine catering to the global market.

image
Business Standard
177 22
Widgets Magazine

More News

Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard